Note that analysts ABBV stock forecasts can be wrong. ABBV Stock Forecast Price Target for 2024 TradingView ABBV currently yields 4.1% and has raised its dividend every year since 2013. A major reason behind Abbvies stellar performance amid the ongoing economic crises is the resolution of the companys Humira (adalimumab) litigation with Alvotech in March 2022. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Epcoritamab alone will not be sufficient to get AbbVie where it wants to be - despite some analysts believing it will be the highest grossing Pharma revenue wise by 2026. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. Projections are based on making fundamental and technical studies of the ABBV stock price performance. The Abbvie stock forecast for 2025 had the price at $259.018. The company reported its first revenue for Botox competitor Daxxify. If you rely on the information on this page then you do so entirely on your own risk. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. Aurora Cannabis Stock Forecast for 2023 - 2025 - 2030 I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. Since then, however, the stock price has fallen 18% to. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. AbbVie has 5 focus areas for its research and products. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. Abbvie (ABBV) stock price prediction is 262.23586323343 USD. The Abbvie ABBV has several positive factors pushing its price performance. According to the Abbvie stock technical analysis, as of 30 June, the Relative Strength Index (RSI) was pointing to neutral at 62.18. In-depth profiles and analysis for 20,000 public companies. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. I'm on twitter @edmundingham. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. View AbbVie's Short Interest. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. AbbVie Fair Value Forecast for 2023 - 2025 - 2030 In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 - an increase of 42.06%. This could present more profit potential for drugmakers as well as investors. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. This figure could eventually end up substantially larger - according to Gonzalez: We've begun to see some very exciting data from several solid tumor programs, including our anti-GARP antibody ABBV-151, and our PTK7 ADC, ABBV-647. AbbVie product revenues by quarter and year since FY20. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. All Rights Reserved. You should do your own research and never invest money you cannot afford to lose. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. Myelofibrosis has proved to be a tricky indication for drug developers and there are no wholly satisfactory solutions on the market at present, therefore if approved I would expect Navitoclax - a drug that AbbVie has been working on for some time - to generate a couple of billion dollars in peak sales. How do I arrive at my share price target? That same month, the FDA extended the review period for Skyrizi (risankizumab), a treatment drug for moderate to severe Crohns disease in patients aged 16 and older. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. . What is Richard A. Gonzalez's approval rating as AbbVie's CEO? AbbVie has a P/B Ratio of 15.97. Get short term trading ideas from the MarketBeat Idea Engine. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. In other words, no Humira, no problem! Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. With a 5-year investment, the revenue is expected to be around +88.28%. Your current $100 investment may be up to $188.28 in 2028. On average, they expect the company's stock price to reach $161.12 in the next twelve months. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. View the best growth stocks for 2023 here. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. The surge in revenues can primarily be attributed to its Allergan. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, Chief Financial Officer & Executive Vice President, BREAKING: Tiny biotech successfully treats blindness, Fed's Shocking New Plan to Control Your Money. Our daily ratings and market update email newsletter. Should You Buy AbbVie Stock After The Recent 7% Fall? - Forbes When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. AbbVie projected sales - immunology (my forecasts and assumptions). I wrote this article myself, and it expresses my own opinions. The ex-dividend date of this dividend is Thursday, April 13th. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. Abbvie Inc Stock Forecast, Predictions & Price Target - WallStreetZen In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. Please log in to your account or sign up in order to add this asset to your watchlist. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. During the same quarter in the prior year, the firm posted $3.31 EPS. abbvie stock forecast 2022 - 2025 - 2030 - 2032 AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. One share of ABBV stock can currently be purchased for approximately $156.06. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? writing - trading down slightly from its all-time high of >$160 achieved in early December last year. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. About the AbbVie, Inc. stock forecast. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. View ABBV analyst ratings or view top-rated stocks. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. Forecast target price for 03-06-2023: $ 152.58. (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. AbbVie saw a increase in short interest in February. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. This suggests a possible upside of 3.2% from the stock's current price. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. And never invest or trade money you cannot afford to lose. What other stocks do shareholders of AbbVie own? As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. Data from two Phase 3 induction studies and one maintenance study supported the approval. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. The company issued revenue guidance of -. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. As we can see, as per management's guidance revenues fall between 2022 and 2023, before recovering and growing in each year after. This indicates that AbbVie will be able to sustain or increase its dividend. High institutional ownership can be a signal of strong market trust in this company. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). Please. Past performance is no guarantee of future results. The company has a robust pipeline of new products that are in some stage of clinical trials. I write about Biotech, Pharma and Healthcare stocks and share investment tips. Better Buy: AbbVie vs. Johnson & Johnson | The Motley Fool But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Wallet Investor suggested that the price could hit $300.386 in June 2027. AbbVie Inc. (ABBV) Stock Forecast & Price Targets - Stock Analysis It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. Their ABBV share price forecasts range from $140.00 to $200.00. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. The above table shows quarterly and annual product revenues going back to FY20, whilst the last 4 columns show revenue growth percentage between FY20 and FY21, then revenue growth between Q2'21 and Q2'22, the sequential (quarter on quarter) growth, followed by product sales as a percentage of revenues. There is an element of risk to that as clinical trial failures are common, even for a giant like AbbVie, and even CEO Gonzalez may be forced to backtrack on some of his blockbuster sales projections. The stock projection varied from the low price target of $135 to the high of $200. American Consumer News, LLC dba MarketBeat 2010-2023. AbbVie (ABBV) Stock Forecast & Price Target - TipRanks Management initially blamed slow take-up post pandemic for the drug's declining sales, but Gonzalez also told JPM Conference attendees that "new competitive entrants has significantly lowered our sales expectations for Imbruvica". I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. That certainly won't derail the oncology division however. The five-year dividend growth rate is just below 18%. Johnson & Johnson Stock Forecast 2023 - 2025 - 2030 AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. Let's begin our analysis with the immunology division. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. AbbVie declared a quarterly dividend on Thursday, February 16th. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. AbbVie Stock: A Blue Chip You Cannot Afford To Miss, Yield 4.1% See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. 8.05% Over the years, AbbView Inc. has made numerous acquisitions. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. In February, a Phase 3 induction study saw positive top-line results. Furthermore, it seems sales of Lupron and Synthroid have joined the "All Other" section, which has generated $2.2bn of revenues in the first half of 2022, versus $1.5bn in the first half of 2021. Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. Management puts this down to "delayed market recovery for new patients starting therapy in Chronic Lymphocytic Leukemia ("CLL") and increasing competition" and has downgraded its FY22 guidance as a result. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. AbbVie is a leader in ESG and sustainability. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. ABBV - Abbvie Inc Forecast - CNNMoney.com - CNN Business In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. Trading CFDs is high risk and is not suitable for everyone. This suggests a possible upside of 3.8% from the stock's current price. As such, forecasting stock prices is more of an art than a science. For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. View which stocks are hot on social media with MarketBeat's trending stocks report. The analysts 12-month consensus ABBV stock price target was $159.75.